Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1352

Sort by

Sort Order Select

Journal Articles

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

Blood (2024) 144 (4): 402–407.

https://doi.org/10.1182/blood.2023023557

Published: 2024

Includes: Supplemental data

Journal Articles

RAS/RAF landscape in monoclonal plasma cell conditions

Blood (2024) 144 (2): 201–205.

https://doi.org/10.1182/blood.2023022295

Published: 2024

Includes: Supplemental data

Journal Articles

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Blood (2024) 143 (20): 2053–2058.

https://doi.org/10.1182/blood.2023021184

Published: 2024

Includes: Supplemental data

Journal Articles

Cryo-EM structure and functional basis of prothrombin recognition by a type I antiprothrombin antiphospholipid antibody

Suresh Kumar, Brock Summers, Kathrine Basore, Vittorio Pengo, Robert Flaumenhaft, Nicola Pozzi

Blood (2024) 143 (19): 2005–2011.

https://doi.org/10.1182/blood.2023022942

Published: 2024

Includes: Supplemental data

Journal Articles

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood (2024) 143 (19): 1931–1936.

https://doi.org/10.1182/blood.2023023096

Published: 2024

Includes: Supplemental data

Journal Articles

Single-cell landscape of idiopathic multicentric Castleman disease in identical twins

Blood (2024) 143 (18): 1837–1844.

https://doi.org/10.1182/blood.2023021992

Published: 2024

Includes: Supplemental data

Journal Articles

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

Salma B. Abdelbaky, Brian Giacopelli, Kari G. Rabe, Kyoko Yamaguchi, Yue-Zhong Wu, Huihuang Yan, Tait D. Shanafelt, Sameer A. Parikh, Wei Ding, Paul J. Hampel, Sochilt Brown, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Curtis A. Hanson, Alexander S. Parker, Esteban Braggio, Susan L. Slager, Christopher C. Oakes

Blood (2024) 143 (17): 1752–1757.

https://doi.org/10.1182/blood.2023022180

Published: 2024

Includes: Supplemental data

Journal Articles

CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells

Sofia Mensurado, Carolina Condeço, Diego Sánchez-Martínez, Sara Shirley, Rui M. L. Coelho, Néstor Tirado, Meritxell Vinyoles, Rafael Blanco-Domínguez, Leandro Barros, Beatriz Galvão, Noélia Custódio, Maria Gomes da Silva, Pablo Menéndez, Bruno Silva-Santos

Blood (2024) 143 (15): 1488–1495.

https://doi.org/10.1182/blood.2023022992

Published: 2024

Includes: Supplemental data

Journal Articles

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Blood (2024) 143 (14): 1391–1398.

https://doi.org/10.1182/blood.2023021752

Published: 2024

Includes: Supplemental data

Journal Articles

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Blood (2024) 143 (7): 592–596.

https://doi.org/10.1182/blood.2023022080

Published: 2024

Includes: Supplemental data

Journal Articles

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Blood (2024) 143 (7): 597–603.

https://doi.org/10.1182/blood.2023022083

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney DiNardo, Lucia Masarova, Tapan Kadia, Rebecca S. Garris, Farhad Ravandi, Hagop Kantarjian

Blood (2024) 143 (5): 417–421.

https://doi.org/10.1182/blood.2023022330

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Blood (2024) 143 (4): 336–341.

https://doi.org/10.1182/blood.2023021579

Published: 2024

Includes: Supplemental data

Journal Articles

The bone marrow is the primary site of thrombopoiesis

Nathan L. Asquith, Estelle Carminita, Virginia Camacho, Antonio Rodriguez-Romera, David Stegner, Daniela Freire, Isabelle C. Becker, Kellie R. Machlus, Abdullah O. Khan, Joseph E. Italiano

Blood (2024) 143 (3): 272–278.

https://doi.org/10.1182/blood.2023020895

Published: 2024

Includes: Supplemental data

Journal Articles

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

Blood (2024) 143 (2): 118–123.

https://doi.org/10.1182/blood.2023020621

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Despoina Papazoglou, Xin Victoria Wang, Tait D. Shanafelt, Connie E. Lesnick, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S. Tallman, Neil E. Kay, Alan G. Ramsay

Blood (2024) 143 (1): 57–63.

https://doi.org/10.1182/blood.2023020554

Published: 2024

Includes: Supplemental data

Journal Articles

PF4 activates the c-Mpl–Jak2 pathway in platelets

Richard J. Buka, Samantha J. Montague, Luis A. Moran, Eleyna M. Martin, Alexandre Slater, Steve P. Watson, Phillip L. R. Nicolson

Blood (2024) 143 (1): 64–69.

https://doi.org/10.1182/blood.2023020872

Published: 2024

Includes: Supplemental data

Journal Articles

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Ilaria S. Pagani, Naranie Shanmuganathan, Phuong Dang, Verity A. Saunders, Randall Grose, Chung H. Kok, Jane James, Molly Tolland, Jodi A. Braley, Haley K. Altamura, David T. Yeung, Susan Branford, Agnes S. M. Yong, Timothy P. Hughes, David M. Ross

Blood (2023) 142 (25): 2192–2197.

https://doi.org/10.1182/blood.2023021119

Published: 2023

Includes: Supplemental data

Journal Articles

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Philip A. Thompson, Alexandre Bazinet, William G. Wierda, Constantine S. Tam, Susan M. O’Brien, Satabdi Saha, Christine B. Peterson, William Plunkett, Michael J. Keating

Blood (2023) 142 (21): 1784–1788.

https://doi.org/10.1182/blood.2023020158

Published: 2023

Includes: Supplemental data

Journal Articles

Risk of male breast cancer after Hodgkin lymphoma

Simone de Vries, Inge M. Krul, Michael Schaapveld, Cecile P. M. Janus, Saskia E. Rademakers, Judith M. Roesink, Marten R. Nijziel, Yavuz M. Bilgin, Berthe M. P. Aleman, Flora E. van Leeuwen

Blood (2023) 142 (9): 806–811.

https://doi.org/10.1182/blood.2023020940

Published: 2023

Includes: Supplemental data

NARROW

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

RAS/RAF landscape in monoclonal plasma cell conditions

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Cryo-EM structure and functional basis of prothrombin recognition by a type I antiprothrombin antiphospholipid antibody

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Single-cell landscape of idiopathic multicentric Castleman disease in identical twins

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

The bone marrow is the primary site of thrombopoiesis

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

PF4 activates the c-Mpl–Jak2 pathway in platelets

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Risk of male breast cancer after Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only